NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date:** Tuesday 5 November 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Michael Chambers Present for all items
4. Dawn Cooper Present for all items
5. Dr Mark Corbett Present for all items
6. Dr Prithwiraj Das Present for all items
7. Dr David Foreman Present for all items
8. John Hampson Present for all items
9. Dr Steven Lloyd Present for items 4 to 5.2.2
10. Scott Muir Present for items 5 to 5.2.2
11. Ugochi Nwulu Present for items 1 to 4.2.2
12. Stella O’Brien Present for all items
13. Dr Clare Offer Present for all items
14. Dr Amit Parekh Present for all items
15. Dr Kate Ren Present for all items
16. Professor Andrew Renehan Present for all items
17. Dr Arpit Srivastava Present for items 1 to 5.2
18. Elizabeth Thurgar Present for all items
19. Dr Satish Venkateshan Present for items 1 to 4.2.2
20. Simon Watts Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Present for all items

Louise Jafferally, Project Manager Present for all items

Albany Chandler, Heath Technology Assessment Adviser items 1 to 4.2.2

Harsimran Sarpal, Heath Technology Assessment Analyst items 1 to 4.2.2

Samuel Slayen, Heath Technology Assessment Adviser items 5 to 5.2.2

Zain Hussain, Heath Technology Assessment Analyst items 5 to 5.2.2

External assessment group representatives present

Archie Walters, BMJ Technology Assessment Group Items 1 to 4.1.3

Vicky Wakefield, BMJ Technology Assessment Group Items 1 to 4.1.3

Geoff Frampton, Southampton Health Technology Assessment Centre Items 5 to 5.1.3

Inês Ribeiro, Southampton Health Technology Assessment Centre Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, CDF Lead, NHS England expert Items 1 to 4.2.2

Dr Cathy Burton, Consultant Haematologist, Clinical expert, nominated by Takeda Items 1 to 4.1.3

Professor Graham Collins, Associate Professor of Haematology and Consultant Haematologist, Clinical expert, nominated by Takeda Items 1 to 4.1.3

Susannah Wood, Health Information Officer, Lymphoma Action, Patient expert, nominated by Lymphoma Action Items 1 to 4.1.3

Dr David Lowe, Consultant Clinical Immunologist, Clinical expert, nominated by the British Society for Immunology Items 5 to 5.1.3

Dr Brendan Payne, Consultant Virologist & Infectious Diseases Physician, Clinical expert, nominated by Merck Sharp & Dohme Items 5 to 5.1.3

Robert Burns, Chair, Cardiothoracic Transplant Patient Group, Patient expert, nominated by the Cardiothoracic Transplant Patient Group, NHS Blood and Transplant

Items 5 to 5.1.3

Dr Susannah Thompson, Patient expert, nominated by Long Covid SOS

Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair, Prof. Steve O’Brien, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Alex Cale, Iain McGowan, Louise Hunt and Dr Pedro Saramago.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 2 October 2024

### Appraisal of brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Tadeka UK
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11384).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Clare Offer, Dr Kate Ren and Stella O’Brien.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11384>

### Appraisal of molnupiravir for treating COVID-19 [ID6340]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11409).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by John Hampson, Dr Mark Corbett and Stella O’Brien.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11409>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Wednesday 4 December 2024 and will start promptly at 9am.